Biolegend, 593924, Cell-Vive™ GMP Recombinant Human LIF (carrier-free)
50microg
Catalog Number: 593924
Send an RFQ.
Category
Loading…
| Source | Human LIF, amino acids (Ser23-Phe202) (Accession# NP_002300.1), was expressed in E. coli. |
|---|---|
| Molecular Mass | The 180 amino acid recombinant protein has a predicted molecular mass of approximately 20 kD. The protein migrates at about 20 kD in DTT-reducing conditions and about 18 kD in non-reducing condition by SDS-PAGE. The N-terminal amino acid is Ser. |
| N-terminalSequence Analysis | Ser-Pro-Leu-Pro-Ile-Thr-Pro-Val-Asn-Ala |
| Purity | ≥ 95%, as determined by Coomassie stained SDS-PAGE |
| Formulation | Protein was lyophilized from 0.22 μm filtered solution containing PBS, pH 7.4 |
| Endotoxin Level | Less than or equal to 0.1 EU per μg of protein as determined by LAL method |
| Residual Host Cell Protein Content | ≤ 0.500 ng/μg by ELISA |
| Concentration | 50 μg size is lyophilized |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Storage & Handling |
|---|
| Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at - 20°C or colder until the expiration date. Reconstitute lyophilized protein in sterile PBS. Before reconstitution, make sure sterile PBS and product are at room temperature. Quickly spin the vial or gently tap down on the vial to make sure the lyophilized product is at the bottom of the vial before opening. Use aseptic techniques to add the required volume of reconstitution buffer (sterile PBS) to the vial, to obtain the recommended stock concentration 250 μg/mL. Close the vial and leave at ambient temperature for 15-20 minutes. Then gently invert the vial several times or until all of the lyophilized product dissolves. Leave the vial at room temperature for another 15 minutes. If small particulates are still observed after 15 minutes, incubate at room temperature for an additional 30 minutes and leave the vial at 2°C - 8°C overnight. Next day, invert the vial several times or gently pipette the solution up and down before use. If needed, transfer the reconstituted stock solution to a sterile container for additional dilution to no less than 100 μg/mL. Small working aliquots in polypropylene tubes can be made after reconstitution and store the vials at -20°C or lower. Avoid freeze/ thaw cycles. Carrier protein such as 0.2 - 1% endotoxin-free BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to two weeks or stored at -20°C or colder for up to 3 months. |
| Activity | Human LIF induces proliferation of TF-1 cells in a dose-dependent manner. ED50 = 0.03-0.12 ng/mL. The specific activity of Cell-Vive™ GMP Recombinant Human LIF (carrier-free) is ≥1.4 x 107 IU/mg when compared against the WHO International Standard for Human LIF (NIBSC code: 93/562). |
|---|
| Application | Bioassay - Quality tested |
|---|
| Application Notes | Our lyophilized proteins are validated in-house to maintain activity after shipping at ambient temperature and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected]. |
|---|
| Application References(PubMed link indicates BioLegend citation) | Li P, et al. 2022. EMBO Mol Med. 14:e14511. PubMed |
|---|
| Disclaimer | BioLegend Cell-Vive™ GMP Recombinant proteins are for research use only. Suitable for ex vivo cell processing. Not for injection or diagnostic or therapeutic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products. |
|---|
| Bioactivity | Human LIF induces proliferation of TF-1 cells. |
|---|
| Cell Sources | Expressed in the trophectoderm of the developing embryo, activated CD4+ T cells. |
|---|
| Cell Targets | Embryonic stem cells. |
|---|
| Receptors | LIFR complex (gp190 and gp130). |
|---|
| Antigen References | Moreau JF, et al. 1988. Nature. 336:690. Tomida M, et al. 1993. FEBS Lett. 334:193. Metcalfe SM. 2011. Genes Immun. 12:157. Voyle RB, et al. 1999. Exp. Cell Res. 249:199. Slaets H, et al. 2010. Trends Mol. Med. 16:493. Souza PP, et al. 2012. Mol. Immunol. 49:601. |
|---|
| Regulation | Inhibits embryonic stem cell differentiation, induces the terminal differentiation of myeloid leukemia cells. LIF is upregulated by TNFα and IL-17. LIF is downregulated by IL-4 and IL-13 in fibroblasts |
|---|
| Gene ID | 3976 |
|---|
| UniProt | View information about LIF on UniProt.org |
|---|
| Other Names | Leukemia inhibitory factor, HILDA (human interleukin in DA cells), MLPLI (melanoma-derived LPL inhibitor), DIA (differentiation-inducing factor) |
|---|
